Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,115 public posts
Filter results
CTC Count Can Predict Outcome in Prostate Cancer - Dr Goldkorn describes the valuable biomarker that will help guide treatment -MedPageToday
From the MedPageToday interview article:[i] [/i] [i]"Baseline circulating tumor cell (CTC) count was found to be significantly predictive of clinical outcome in a phase III trial of metastatic
castration
-sensitive prostate cancer (mCSPC) presented at the 2020 American Society of Clinical Oncology
From the MedPageToday interview article:[i] [/i] [i]"Baseline circulating tumor cell (CTC) count was found to be significantly predictive of clinical outcome in a phase III trial of metastatic
castration
-sensitive prostate cancer (mCSPC) presented at the 2020 American Society of Clinical Oncology
cujoe
in
Fight Prostate Cancer
4 years ago
Final 5-yr Survival analysis in the PREVAIL trial.
Keywords: Enzalutamide; Metastatic
castration
-resistant prostate cancer; Multivariable model; Overall survival; Prostate-specific antigen; Safety. Copyright © 2020. Published by Elsevier B.V.
Keywords: Enzalutamide; Metastatic
castration
-resistant prostate cancer; Multivariable model; Overall survival; Prostate-specific antigen; Safety. Copyright © 2020. Published by Elsevier B.V.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Outcomes in Men With Locally Advanced Prostate Cancer Treated With Neoadjuvant ADT and EBRT Followed by Adjuvant Continuous/Intermittent ADT
The primary endpoint was modified biochemical relapse-free survival (bRFS) with respect to nonmetastatic
castration
-resistant prostate cancer (nmCRPC) progression, clinical relapse, or any cause of death. RESULTS The median follow-up time after randomization was 8.2 years.
The primary endpoint was modified biochemical relapse-free survival (bRFS) with respect to nonmetastatic
castration
-resistant prostate cancer (nmCRPC) progression, clinical relapse, or any cause of death. RESULTS The median follow-up time after randomization was 8.2 years.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
FDA Approves First PARP Inhibitor Rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-
castration
-resistant-prostate This article explains why the BRCA mutation was mandated (as is prior treatment with an AR-directed therapy and taxane chemotherapy and ongoing chemical or physical
castration
).
https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-
castration
-resistant-prostate This article explains why the BRCA mutation was mandated (as is prior treatment with an AR-directed therapy and taxane chemotherapy and ongoing chemical or physical
castration
).
Tall_Allen
in
Advanced Prostate Cancer
4 years ago
Association Between Dihydrotestosterone and Long-Term Risk for PCa Mortality
Ever since Huggins discovered that
castration
offered palliation for men with PCa, albeit temporary, there has been a belief that testosterone [T[ acts like gasoline on a fire.
Ever since Huggins discovered that
castration
offered palliation for men with PCa, albeit temporary, there has been a belief that testosterone [T[ acts like gasoline on a fire.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Searches not working! ie - TAS3681 - wondering if anyone is in this trial:Study of TAS3681 in Metastatic Castration Resistant Prostate Canc
https://healthunlocked.com/advanced-prostate-cancer/posts/138818885/trc253-trial I'm particularly interested in this clinical trial as it appears it's a rare find as it may not disqualify patients who are in bone marrow failure: Study of TAS3681 in Metastatic
Castration
Resistant Prostate Cancer https
https://healthunlocked.com/advanced-prostate-cancer/posts/138818885/trc253-trial I'm particularly interested in this clinical trial as it appears it's a rare find as it may not disqualify patients who are in bone marrow failure: Study of TAS3681 in Metastatic
Castration
Resistant Prostate Cancer https
JLS1
in
Advanced Prostate Cancer
4 years ago
FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
From the FDA: https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-
castration
-resistant-prostate And to help understand the basics of PARP inhibitors in BRCA mutated PCa, here is an brief overview from CancerConnect: https://news.cancerconnect.com/prostate-cancer
From the FDA: https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-
castration
-resistant-prostate And to help understand the basics of PARP inhibitors in BRCA mutated PCa, here is an brief overview from CancerConnect: https://news.cancerconnect.com/prostate-cancer
cujoe
in
Fight Prostate Cancer
4 years ago
Nuclear Receptor ERRα Contributes to Castration-Resistant Growth of Prostate Cancer via Its Regulation of Intratumoral Androgen Biosynthesis
The enzyme acts to circumvent
castration
by producing potent androgens that drive proliferation. Furthermore, AKR1C3 mediates chemotherapeutic resistance to the standard of care, enzalutamide, a structural analogue of apalutamide.
The enzyme acts to circumvent
castration
by producing potent androgens that drive proliferation. Furthermore, AKR1C3 mediates chemotherapeutic resistance to the standard of care, enzalutamide, a structural analogue of apalutamide.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Hope the link below works “Key Points Question Does inheritance of the adrenal-permissive HSD3B1(1245C) allele indicate probable worse clinical outcomes in men treated with androgen deprivation therapy with or without docetaxel for metastatic
castration
-sensitive prostate cancer?
Hope the link below works “Key Points Question Does inheritance of the adrenal-permissive HSD3B1(1245C) allele indicate probable worse clinical outcomes in men treated with androgen deprivation therapy with or without docetaxel for metastatic
castration
-sensitive prostate cancer?
podsart
in
Advanced Prostate Cancer
4 years ago
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer in patients with PSADT <10 months.
Mean overall survival was 67 months. "Enzalutamide was associated with a delay in the use of a new subsequent antineoplastic therapy (hazard ratio for the use of any subsequent antineoplastic therapy, 0.29; 95% CI, 0.25 to 0.35) (Fig. S2A). The median time to first use of new antineoplastic therapy
Mean overall survival was 67 months. "Enzalutamide was associated with a delay in the use of a new subsequent antineoplastic therapy (hazard ratio for the use of any subsequent antineoplastic therapy, 0.29; 95% CI, 0.25 to 0.35) (Fig. S2A). The median time to first use of new antineoplastic therapy
tango65
in
Advanced Prostate Cancer
4 years ago
Ipatasertib - Phase III study with Abiraterone,
So it's no great surprise to discover that: "[i]Phase 3 data showed that the addition of the AKT inhibitor ipatasertib to standard therapy boosted radiographic progression-free survival in patients with advanced
castration
-resistant prostate cancer whose tumors had PTEN loss[/i]."
So it's no great surprise to discover that: "[i]Phase 3 data showed that the addition of the AKT inhibitor ipatasertib to standard therapy boosted radiographic progression-free survival in patients with advanced
castration
-resistant prostate cancer whose tumors had PTEN loss[/i]."
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug
term=Veru-111&rank=1 Sounds safe, even for those with very low blood counts: "In preclinical effectiveness and toxicity studies, orally administered VERU-111 demonstrated significant antitumor activity against
castration
and novel androgen blocking agent (abiraterone or enzalutamide) resistant human
term=Veru-111&rank=1 Sounds safe, even for those with very low blood counts: "In preclinical effectiveness and toxicity studies, orally administered VERU-111 demonstrated significant antitumor activity against
castration
and novel androgen blocking agent (abiraterone or enzalutamide) resistant human
JLS1
in
Advanced Prostate Cancer
4 years ago
RP vs radiation. Survival from time of metastasis.
"One theory for the finding is that [u]early use of ADT as well as RT may potentiate epithelial-mesenchymal transition[/u], which mediates tumor invasion, metastasis, and development of
castration
-resistant tumors, leading to a worse outcome ..."
"One theory for the finding is that [u]early use of ADT as well as RT may potentiate epithelial-mesenchymal transition[/u], which mediates tumor invasion, metastasis, and development of
castration
-resistant tumors, leading to a worse outcome ..."
pjoshea13
in
Advanced Prostate Cancer
4 years ago
NF-κB Signaling Promotes Castration-Resistant Prostate Cancer Initiation and Progression
Unfortunately, patients with advanced PCa can develop incurable
castration
-resistant PCa (CRPCa) due to mutated, variant, or overexpressed AR. Conversely, low or no AR accumulation or activity can also underlie
castration
resistance.
Unfortunately, patients with advanced PCa can develop incurable
castration
-resistant PCa (CRPCa) due to mutated, variant, or overexpressed AR. Conversely, low or no AR accumulation or activity can also underlie
castration
resistance.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
COVID-19, ADT & the Immune Response
"The atrophy is due to the increased circulating level of sex hormones, and chemical or physical
castration
of an adult results in the thymus increasing in size and activity." *** Who knew that ADT had an upside?
"The atrophy is due to the increased circulating level of sex hormones, and chemical or physical
castration
of an adult results in the thymus increasing in size and activity." *** Who knew that ADT had an upside?
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Frailty, G-8 Score & PCa outcome.
The overall survival was significantly different between Geriatric 8 scores ≤13 and >13 in metastatic hormone-naïve prostate cancer patients, and between Geriatric 8 scores ≤12 and >12 in
castration
-resistant prostate cancer patients.
The overall survival was significantly different between Geriatric 8 scores ≤13 and >13 in metastatic hormone-naïve prostate cancer patients, and between Geriatric 8 scores ≤12 and >12 in
castration
-resistant prostate cancer patients.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Any experience cabazitaxel (Jevtana)without prednisone? Referencing preliminary report published Aug 2017.
A preliminary report published in Journal of Cancer, August 2017, entitled ““Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic
Castration
-Resistant Prostate Cancer” studied 91 patients in Italy and showed median survival 9 months with prednisone and 14 months without it, without
A preliminary report published in Journal of Cancer, August 2017, entitled ““Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic
Castration
-Resistant Prostate Cancer” studied 91 patients in Italy and showed median survival 9 months with prednisone and 14 months without it, without
Barbara345
in
Advanced Prostate Cancer
4 years ago
Olaparib for Metastatic Castration-Resistant Prostate Cancer
The New England Journal of Medicine Olaparib for Metastatic
Castration
-Resistant Prostate Cancer N. Engl. J. Med 2020 Apr 28;[EPub Ahead of Print], J de Bono, J Mateo, K Fizazi, e
The New England Journal of Medicine Olaparib for Metastatic
Castration
-Resistant Prostate Cancer N. Engl. J. Med 2020 Apr 28;[EPub Ahead of Print], J de Bono, J Mateo, K Fizazi, e
Balsam01
in
Advanced Prostate Cancer
4 years ago
Rosuvastatin [Crestor] and Abiraterone [Zytiga]
PMID: 32397905 DOI: 10.1177/1078155220923001 Abstract Introduction: Abiraterone acetate is an inhibitor of androgens biosynthesis, approved as first-line treatment in
castration
-resistant prostate cancer and metastatic
castration
-sensitive prostate cancer.
PMID: 32397905 DOI: 10.1177/1078155220923001 Abstract Introduction: Abiraterone acetate is an inhibitor of androgens biosynthesis, approved as first-line treatment in
castration
-resistant prostate cancer and metastatic
castration
-sensitive prostate cancer.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor. 2020 Mar 3
The enzyme acts to circumvent
castration
by producing potent androgens that drive proliferation. Furthermore, AKR1C3 mediates chemotherapeutic resistance to the standard of care; Enzalutamide, a structural analogue of Apalutamide.
The enzyme acts to circumvent
castration
by producing potent androgens that drive proliferation. Furthermore, AKR1C3 mediates chemotherapeutic resistance to the standard of care; Enzalutamide, a structural analogue of Apalutamide.
JLS1
in
Advanced Prostate Cancer
4 years ago
1
...
29
30
31
...
56
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
992 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest